| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 21 | 2023 | 846 | 1.950 |
Why?
|
| Cerebral Hemorrhage | 11 | 2022 | 110 | 1.220 |
Why?
|
| Deep Brain Stimulation | 7 | 2022 | 40 | 1.130 |
Why?
|
| Fragile X Syndrome | 5 | 2020 | 192 | 0.950 |
Why?
|
| Female | 62 | 2022 | 15583 | 0.800 |
Why?
|
| Male | 60 | 2022 | 15173 | 0.790 |
Why?
|
| Intracranial Aneurysm | 4 | 2014 | 39 | 0.740 |
Why?
|
| Stroke | 6 | 2018 | 272 | 0.730 |
Why?
|
| Humans | 75 | 2023 | 28117 | 0.710 |
Why?
|
| Aged | 44 | 2022 | 9223 | 0.670 |
Why?
|
| Safety-net Providers | 1 | 2019 | 7 | 0.650 |
Why?
|
| Hospitals, Public | 1 | 2019 | 25 | 0.650 |
Why?
|
| Sarcoidosis | 1 | 2019 | 14 | 0.640 |
Why?
|
| Central Nervous System Diseases | 1 | 2019 | 18 | 0.640 |
Why?
|
| Middle Aged | 39 | 2022 | 9188 | 0.610 |
Why?
|
| Aneurysm, Ruptured | 2 | 2014 | 16 | 0.570 |
Why?
|
| Subthalamic Nucleus | 4 | 2022 | 20 | 0.550 |
Why?
|
| Hallucinations | 3 | 2011 | 64 | 0.540 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2022 | 96 | 0.520 |
Why?
|
| Retrospective Studies | 23 | 2021 | 3537 | 0.500 |
Why?
|
| Thrombolytic Therapy | 3 | 2016 | 46 | 0.500 |
Why?
|
| Fibrinolytic Agents | 3 | 2011 | 56 | 0.480 |
Why?
|
| Self-Help Groups | 1 | 2014 | 8 | 0.480 |
Why?
|
| Length of Stay | 6 | 2018 | 328 | 0.480 |
Why?
|
| Ataxia | 3 | 2020 | 78 | 0.470 |
Why?
|
| Thrombectomy | 3 | 2021 | 29 | 0.470 |
Why?
|
| Cholesterol | 1 | 2014 | 55 | 0.470 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2016 | 40 | 0.460 |
Why?
|
| Severity of Illness Index | 10 | 2020 | 991 | 0.460 |
Why?
|
| Tremor | 3 | 2020 | 117 | 0.460 |
Why?
|
| Adult | 23 | 2021 | 8036 | 0.440 |
Why?
|
| Social Media | 1 | 2014 | 47 | 0.440 |
Why?
|
| Brain Ischemia | 3 | 2021 | 63 | 0.430 |
Why?
|
| Seizures | 3 | 2019 | 67 | 0.420 |
Why?
|
| Biostatistics | 1 | 2012 | 5 | 0.420 |
Why?
|
| Glucosylceramidase | 3 | 2022 | 17 | 0.420 |
Why?
|
| Bayes Theorem | 1 | 2012 | 42 | 0.410 |
Why?
|
| Heart Transplantation | 1 | 2012 | 30 | 0.410 |
Why?
|
| Risk Factors | 14 | 2021 | 2375 | 0.400 |
Why?
|
| Hospital Mortality | 4 | 2017 | 146 | 0.390 |
Why?
|
| Health Facilities | 1 | 2011 | 22 | 0.390 |
Why?
|
| Databases, Factual | 4 | 2022 | 354 | 0.380 |
Why?
|
| Hematoma, Subdural, Acute | 3 | 2017 | 7 | 0.380 |
Why?
|
| Postoperative Complications | 4 | 2018 | 930 | 0.360 |
Why?
|
| Young Adult | 10 | 2021 | 2048 | 0.350 |
Why?
|
| Quality of Life | 5 | 2022 | 656 | 0.340 |
Why?
|
| Accidental Falls | 3 | 2020 | 114 | 0.330 |
Why?
|
| Cognition Disorders | 4 | 2021 | 1019 | 0.330 |
Why?
|
| Parkinsonian Disorders | 3 | 2022 | 227 | 0.330 |
Why?
|
| Gait | 4 | 2020 | 412 | 0.320 |
Why?
|
| Treatment Outcome | 15 | 2021 | 3531 | 0.320 |
Why?
|
| Diet, Ketogenic | 2 | 2019 | 5 | 0.320 |
Why?
|
| Drug Resistant Epilepsy | 2 | 2019 | 10 | 0.320 |
Why?
|
| Disease Progression | 1 | 2011 | 718 | 0.310 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 4846 | 0.310 |
Why?
|
| Brain | 5 | 2021 | 1690 | 0.290 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2020 | 139 | 0.280 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 492 | 0.280 |
Why?
|
| Patient Transfer | 2 | 2017 | 23 | 0.260 |
Why?
|
| Neuropsychological Tests | 5 | 2022 | 1258 | 0.260 |
Why?
|
| Illinois | 3 | 2019 | 246 | 0.260 |
Why?
|
| Mentors | 2 | 2023 | 43 | 0.260 |
Why?
|
| Time Factors | 8 | 2020 | 1489 | 0.260 |
Why?
|
| Caregivers | 3 | 2023 | 198 | 0.250 |
Why?
|
| Biopsy | 2 | 2019 | 218 | 0.250 |
Why?
|
| Trinucleotide Repeat Expansion | 3 | 2020 | 46 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2022 | 1181 | 0.250 |
Why?
|
| Mutation | 3 | 2022 | 358 | 0.240 |
Why?
|
| Hospitalization | 3 | 2020 | 320 | 0.230 |
Why?
|
| Fragile X Mental Retardation Protein | 3 | 2020 | 118 | 0.230 |
Why?
|
| Hematoma, Subdural | 2 | 2015 | 7 | 0.230 |
Why?
|
| Heterozygote | 2 | 2022 | 98 | 0.230 |
Why?
|
| Prospective Studies | 10 | 2021 | 1763 | 0.230 |
Why?
|
| Prognosis | 4 | 2020 | 819 | 0.220 |
Why?
|
| Attention | 3 | 2020 | 139 | 0.220 |
Why?
|
| Postural Balance | 2 | 2021 | 121 | 0.210 |
Why?
|
| Psychometrics | 2 | 2014 | 243 | 0.210 |
Why?
|
| Child, Preschool | 4 | 2021 | 678 | 0.210 |
Why?
|
| Case-Control Studies | 8 | 2020 | 585 | 0.210 |
Why?
|
| Walking Speed | 2 | 2020 | 40 | 0.210 |
Why?
|
| Spinal Fusion | 3 | 2018 | 474 | 0.210 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2011 | 40 | 0.210 |
Why?
|
| Homebound Persons | 1 | 2022 | 6 | 0.200 |
Why?
|
| Physical Therapists | 1 | 2022 | 3 | 0.200 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2022 | 22 | 0.200 |
Why?
|
| Cerebral Amyloid Angiopathy | 3 | 2019 | 114 | 0.200 |
Why?
|
| Blood Pressure Determination | 1 | 2022 | 16 | 0.200 |
Why?
|
| Executive Function | 3 | 2018 | 116 | 0.200 |
Why?
|
| Arterial Pressure | 1 | 2022 | 14 | 0.200 |
Why?
|
| Cognitive Dysfunction | 4 | 2020 | 1035 | 0.200 |
Why?
|
| Lewy Body Disease | 1 | 2023 | 99 | 0.200 |
Why?
|
| Psychomotor Performance | 2 | 2020 | 214 | 0.200 |
Why?
|
| Weather | 2 | 2019 | 13 | 0.200 |
Why?
|
| Mentoring | 1 | 2022 | 31 | 0.200 |
Why?
|
| Pilot Projects | 5 | 2023 | 435 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 758 | 0.190 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 1368 | 0.190 |
Why?
|
| Medical Futility | 1 | 2021 | 4 | 0.190 |
Why?
|
| Leukoaraiosis | 1 | 2021 | 8 | 0.190 |
Why?
|
| Multidetector Computed Tomography | 1 | 2021 | 11 | 0.190 |
Why?
|
| Adolescent | 8 | 2021 | 2291 | 0.180 |
Why?
|
| Cognition | 4 | 2022 | 1354 | 0.180 |
Why?
|
| Sleep Wake Disorders | 2 | 2013 | 120 | 0.180 |
Why?
|
| Martial Arts | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hyperglycemia | 1 | 2020 | 33 | 0.180 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 177 | 0.180 |
Why?
|
| Telemedicine | 1 | 2022 | 110 | 0.170 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.170 |
Why?
|
| Blood Glucose | 1 | 2020 | 108 | 0.170 |
Why?
|
| Nootropic Agents | 1 | 2020 | 15 | 0.170 |
Why?
|
| Decompression, Surgical | 2 | 2018 | 130 | 0.170 |
Why?
|
| Odds Ratio | 4 | 2017 | 269 | 0.170 |
Why?
|
| Depression | 2 | 2016 | 453 | 0.170 |
Why?
|
| Arm | 1 | 2020 | 84 | 0.160 |
Why?
|
| Huntington Disease | 1 | 2020 | 51 | 0.160 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 28 | 0.160 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2019 | 8 | 0.160 |
Why?
|
| Movement Disorders | 1 | 2020 | 91 | 0.160 |
Why?
|
| Child | 5 | 2022 | 1410 | 0.160 |
Why?
|
| Microelectrodes | 1 | 2018 | 18 | 0.160 |
Why?
|
| Electrodes, Implanted | 1 | 2018 | 21 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2019 | 106 | 0.150 |
Why?
|
| Middle Cerebral Artery | 1 | 2018 | 7 | 0.150 |
Why?
|
| Carotid Artery, Internal | 1 | 2018 | 8 | 0.150 |
Why?
|
| Walking | 1 | 2020 | 260 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 117 | 0.150 |
Why?
|
| Tertiary Care Centers | 2 | 2015 | 67 | 0.150 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2017 | 5 | 0.150 |
Why?
|
| Phenotype | 1 | 2019 | 307 | 0.150 |
Why?
|
| Lumbosacral Region | 1 | 2018 | 65 | 0.140 |
Why?
|
| Corpus Striatum | 1 | 2018 | 66 | 0.140 |
Why?
|
| Dopamine | 1 | 2018 | 90 | 0.140 |
Why?
|
| Cerebral Ventriculitis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Ventriculostomy | 1 | 2017 | 5 | 0.140 |
Why?
|
| Meningitis, Bacterial | 1 | 2017 | 4 | 0.140 |
Why?
|
| Meningitis, Aseptic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2018 | 75 | 0.140 |
Why?
|
| Lactic Acid | 1 | 2017 | 10 | 0.140 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2017 | 11 | 0.140 |
Why?
|
| Disability Evaluation | 5 | 2021 | 290 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2018 | 123 | 0.140 |
Why?
|
| Fever | 1 | 2017 | 36 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2017 | 98 | 0.140 |
Why?
|
| Unemployment | 1 | 2016 | 2 | 0.140 |
Why?
|
| Epilepsy | 1 | 2017 | 65 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2017 | 184 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 170 | 0.130 |
Why?
|
| Substantia Nigra | 1 | 2016 | 126 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 120 | 0.130 |
Why?
|
| Diskectomy | 1 | 2018 | 186 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2018 | 1890 | 0.130 |
Why?
|
| Anxiety | 1 | 2016 | 156 | 0.120 |
Why?
|
| alpha-Synuclein | 1 | 2016 | 132 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2015 | 45 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 41 | 0.120 |
Why?
|
| Logistic Models | 5 | 2017 | 397 | 0.120 |
Why?
|
| Cervical Vertebrae | 1 | 2018 | 295 | 0.120 |
Why?
|
| Vascular Access Devices | 1 | 2013 | 4 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 115 | 0.110 |
Why?
|
| Neoplasms | 1 | 2016 | 236 | 0.110 |
Why?
|
| Cerebral Arteries | 1 | 2013 | 25 | 0.110 |
Why?
|
| Cerebral Angiography | 1 | 2013 | 35 | 0.110 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 411 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 69 | 0.110 |
Why?
|
| Stochastic Processes | 1 | 2012 | 13 | 0.110 |
Why?
|
| Biomarkers | 3 | 2022 | 583 | 0.100 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2012 | 6 | 0.100 |
Why?
|
| House Calls | 2 | 2022 | 23 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2012 | 71 | 0.100 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2012 | 24 | 0.100 |
Why?
|
| Menopause, Premature | 1 | 2012 | 6 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2012 | 128 | 0.100 |
Why?
|
| Temporal Lobe | 1 | 2012 | 86 | 0.100 |
Why?
|
| Health Facility Size | 1 | 2011 | 3 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 31 | 0.100 |
Why?
|
| International Classification of Diseases | 1 | 2011 | 12 | 0.100 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 134 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2011 | 22 | 0.100 |
Why?
|
| Radiography | 4 | 2015 | 640 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2011 | 96 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 1201 | 0.100 |
Why?
|
| Ischemic Attack, Transient | 1 | 2011 | 18 | 0.100 |
Why?
|
| Incidence | 3 | 2019 | 757 | 0.090 |
Why?
|
| Certification | 1 | 2011 | 49 | 0.090 |
Why?
|
| Cholecystokinin | 1 | 2011 | 7 | 0.090 |
Why?
|
| Mental Status Schedule | 1 | 2011 | 97 | 0.090 |
Why?
|
| Circle of Willis | 1 | 2011 | 5 | 0.090 |
Why?
|
| Communication Disorders | 1 | 2011 | 5 | 0.090 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 3 | 0.090 |
Why?
|
| Chicago | 3 | 2021 | 905 | 0.090 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 20 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2011 | 91 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2022 | 231 | 0.090 |
Why?
|
| Vitamin B Deficiency | 1 | 2010 | 1 | 0.090 |
Why?
|
| Medication Errors | 1 | 2010 | 15 | 0.090 |
Why?
|
| Vitamin B Complex | 1 | 2010 | 6 | 0.090 |
Why?
|
| Reference Values | 2 | 2021 | 201 | 0.090 |
Why?
|
| Walk Test | 2 | 2020 | 10 | 0.090 |
Why?
|
| Prevalence | 4 | 2013 | 466 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 284 | 0.090 |
Why?
|
| Sleep | 1 | 2013 | 338 | 0.080 |
Why?
|
| Atmospheric Pressure | 2 | 2019 | 8 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 383 | 0.080 |
Why?
|
| Brain Infarction | 1 | 2009 | 75 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 291 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2022 | 511 | 0.080 |
Why?
|
| Hypertension | 3 | 2018 | 225 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2017 | 665 | 0.070 |
Why?
|
| Age Factors | 3 | 2017 | 790 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1811 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 321 | 0.070 |
Why?
|
| Alleles | 2 | 2020 | 209 | 0.060 |
Why?
|
| Range of Motion, Articular | 2 | 2020 | 711 | 0.060 |
Why?
|
| False Positive Reactions | 2 | 2017 | 36 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 145 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2018 | 298 | 0.060 |
Why?
|
| Comorbidity | 2 | 2017 | 497 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 35 | 0.050 |
Why?
|
| Prebiotics | 1 | 2023 | 23 | 0.050 |
Why?
|
| Learning | 1 | 2023 | 71 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2014 | 58 | 0.050 |
Why?
|
| Survivors | 2 | 2015 | 72 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 108 | 0.050 |
Why?
|
| Radial Artery | 1 | 2022 | 8 | 0.050 |
Why?
|
| Blindness | 1 | 2022 | 12 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 2123 | 0.050 |
Why?
|
| Atrophy | 1 | 2021 | 91 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 41 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2022 | 202 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 154 | 0.050 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 4 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 288 | 0.040 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 17 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 64 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 45 | 0.040 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2019 | 3 | 0.040 |
Why?
|
| Neurosurgeons | 1 | 2018 | 7 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 21 | 0.040 |
Why?
|
| Temperature | 1 | 2018 | 67 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 46 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2018 | 59 | 0.040 |
Why?
|
| United States | 2 | 2018 | 2161 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 45 | 0.040 |
Why?
|
| Independent Living | 1 | 2021 | 308 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2020 | 670 | 0.040 |
Why?
|
| Putamen | 1 | 2018 | 21 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 53 | 0.040 |
Why?
|
| Cameroon | 1 | 2017 | 1 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 11 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 140 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 32 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 58 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 121 | 0.040 |
Why?
|
| Motor Activity | 1 | 2020 | 331 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2017 | 25 | 0.030 |
Why?
|
| Body Temperature Regulation | 1 | 2017 | 21 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 43 | 0.030 |
Why?
|
| Olfactory Bulb | 1 | 2016 | 18 | 0.030 |
Why?
|
| Locus Coeruleus | 1 | 2016 | 22 | 0.030 |
Why?
|
| Heart Failure | 1 | 2018 | 173 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 125 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2017 | 56 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2017 | 80 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 182 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 297 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 424 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 9 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 149 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 328 | 0.030 |
Why?
|
| Infant | 1 | 2017 | 591 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 24 | 0.030 |
Why?
|
| Probability | 1 | 2014 | 91 | 0.030 |
Why?
|
| Ventilator Weaning | 1 | 2015 | 37 | 0.030 |
Why?
|
| Language | 1 | 2014 | 68 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2013 | 13 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 30 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 12 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2015 | 97 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2015 | 162 | 0.030 |
Why?
|
| Sleep Stages | 1 | 2013 | 26 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2014 | 168 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2015 | 128 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2013 | 109 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2015 | 292 | 0.030 |
Why?
|
| HIV Infections | 1 | 2017 | 481 | 0.020 |
Why?
|
| Models, Economic | 1 | 2011 | 8 | 0.020 |
Why?
|
| Decision Trees | 1 | 2011 | 14 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2011 | 21 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 51 | 0.020 |
Why?
|
| Memory | 1 | 2013 | 309 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 132 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 61 | 0.020 |
Why?
|
| Social Behavior Disorders | 1 | 2011 | 5 | 0.020 |
Why?
|
| Language Disorders | 1 | 2011 | 7 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 85 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 177 | 0.020 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2010 | 2 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2010 | 7 | 0.020 |
Why?
|
| Vitamin B 6 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 53 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2010 | 13 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2010 | 25 | 0.020 |
Why?
|
| Folic Acid | 1 | 2010 | 21 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 929 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 346 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 141 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 475 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 351 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 441 | 0.020 |
Why?
|